Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
47.38 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 26.823 | 14.24 | 0 | 203.196 | 117.912 | 94.387 | 43.011 | 69.892 | 59.119 | 65.358 | 25.548 | 25.106 | 21.837 |
| Cost of Revenue
| 9.504 | 1.704 | 18.777 | 2.805 | 1.317 | 1.397 | 292.681 | 220.163 | 141.827 | 100.371 | 54.502 | 41.037 | 0 |
| Gross Profit
| 17.319 | 12.536 | -18.777 | 200.391 | 116.595 | 92.99 | -249.67 | -150.271 | -82.708 | -35.013 | -28.954 | -15.931 | 21.837 |
| Gross Profit Ratio
| 0.646 | 0.88 | 0 | 0.986 | 0.989 | 0.985 | -5.805 | -2.15 | -1.399 | -0.536 | -1.133 | -0.635 | 1 |
| Reseach & Development Expenses
| 288.903 | 279.91 | 256.973 | 367.47 | 410.894 | 341.324 | 292.681 | 220.163 | 141.827 | 100.371 | 54.502 | 41.037 | 31.253 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 71.124 | 50.714 | 35.992 | 19.12 | 9.929 | 7.064 | 7.215 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 119.903 | 121.673 | 121.445 | 149.07 | 132.034 | 114.145 | 71.124 | 50.714 | 35.992 | 19.12 | 9.929 | 7.064 | 7.215 |
| Other Expenses
| 6.055 | 6.749 | 14.433 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 408.806 | 401.583 | 378.418 | 516.54 | 542.928 | 455.469 | 363.805 | 270.877 | 177.819 | 119.491 | 64.431 | 48.101 | 38.468 |
| Operating Income
| -391.487 | -389.047 | -378.418 | -316.149 | -426.333 | -362.479 | -320.794 | -200.985 | -118.7 | -54.133 | -38.883 | -22.995 | -16.631 |
| Operating Income Ratio
| -14.595 | -27.321 | 0 | -1.556 | -3.616 | -3.84 | -7.458 | -2.876 | -2.008 | -0.828 | -1.522 | -0.916 | -0.762 |
| Total Other Income Expenses Net
| 39.399 | 157.246 | 21.908 | -11.221 | 14.861 | 16.451 | 6.124 | 2.514 | 0.968 | 0.203 | 0.055 | 0.069 | 0.132 |
| Income Before Tax
| -352.088 | -231.801 | -356.51 | -327.37 | -411.472 | -346.028 | -314.67 | -198.471 | -117.732 | -53.93 | -38.828 | -22.926 | -16.499 |
| Income Before Tax Ratio
| -13.126 | -16.278 | 0 | -1.611 | -3.49 | -3.666 | -7.316 | -2.84 | -1.991 | -0.825 | -1.52 | -0.913 | -0.756 |
| Income Tax Expense
| 6.455 | -157.246 | -1,977.94 | 7.848 | -14.861 | 32.902 | -6.432 | -5.708 | -0.426 | -0.426 | 0.579 | -2.824 | 7.207 |
| Net Income
| -352.088 | -74.555 | 1,604.715 | -335.218 | -396.611 | -346.028 | -314.67 | -198.471 | -117.732 | -53.504 | -39.407 | -20.102 | -23.706 |
| Net Income Ratio
| -13.126 | -5.236 | 0 | -1.65 | -3.364 | -3.666 | -7.316 | -2.84 | -1.991 | -0.819 | -1.542 | -0.801 | -1.086 |
| EPS
| -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| EPS Diluted
| -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| EBITDA
| -384.864 | -526.751 | -385.057 | -309.538 | -418.246 | -362.479 | -320.794 | -200.985 | -118.7 | -54.133 | -38.883 | -21.816 | -15.83 |
| EBITDA Ratio
| -14.348 | -36.991 | 0 | -1.523 | -3.547 | -3.84 | -7.458 | -2.876 | -2.008 | -0.828 | -1.522 | -0.869 | -0.725 |